Gemini Therapeutics Company

Gemini Therapeutics focuses on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases.

Last Funding Type: Series A
Funding Status: Early Stage Venture
Headquarters: Cambridge, Massachusetts, United States
Founded Date: 2015
Investor Type: For Profit
Total Funding: $44.5M
Technology: Rare Genetic Disorders
Employee Number: 11-50
Estimated Revenue: Less than $1M
Investors Number: 3
Industry: Gene Therapy